India Regulator Caps Prices Of Ranbaxy ED Drug, Antibiotic
This article was originally published in PharmAsia News
India's drug price regulator has imposed a cap on the cost of generics of an erectile dysfunction drug and an antibiotic, both made by Ranbaxy Laboratories. The National Pharmaceutical Pricing Authority capped the price of Caverta, Ranbaxy's version of Pfizer's Viagra (sildenafil citrate) and its Cilanem antibiotic injection version of Merck's Primaxin (cilastatin sodium, imipenem). Ranbaxy has asked for a review of the NPPA ruling at the ministerial level, arguing the agency is inconsistent in its pricing decisions for similar drugs. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.